Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?
Executive Summary
Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.
You may also be interested in...
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
PhRMA Lists NAFTA Renegotiation Priorities For Better US Exports
US pharmaceutical industry association PhRMA has laid out what it thinks should be priorities in the upcoming renegotiation of the North American Free Trade Agreement. It wants pricing and reimbursement systems that reward innovation and improved enforcement of patentability standards.
Canada Plans Drug Price Reductions By Changing Reference Country List
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.